Amtagvi’s Complex Path: Why Iovance Is Either a Home Run or a Strikeout

Life Science

Post-Casgevy Era: CRISPR’s Quandary vs. Vertex’s Moat

Life Science

Despite Gains, These 2 Stocks Are Still Worth Buying

Consumer Goods, Life Science

Institutional Buying of PTC Therapeutics Attracts Attention, How Should Retail Investors Position Themselves?

Life Science

Why These Dow Giants Are the New Go-To for Retirement Income

Consumer Goods, Energy, Life Science

Why Novartis Outshines Amarin as a Safe Bet in a Volatile Market

Life Science

Decoding the 2026 Market Leaders: 6 Stocks That Have Already Doubled

Energy, Life Science, Technology

Teva’s Earnings Beat, Stock Doubles: Buy, Sell, or Hold?

Life Science

Temptation of $150 Billion Weight Loss Drug Market Irresistible, Novo Nordisk Expands Production Against the Trend

Life Science

Eli Lilly Soars, Regencell Speculates, but Pfizer’s 6.4% Yield Makes It the Real Value Play

Life Science

Structure Therapeutics Surges 214% in One Year, Faces Institutional Reduction Cashing Out USD 15.52 Million

Life Science

Analysts See 3x Upside Potential, Overlooked Cancer Diagnostics Company Telix Could Be an Investment Dark Horse

Life Science

Patience Pays Off: Why These Two Healthcare Giants Are Worth the Wait

Life Science

Following Billionaire Laffont? Analyzing the Investment Thesis for Moderna

Life Science

Hedge Fund BVF Makes Massive Bet on Structure Therapeutics as Stock Skyrockets 214%

Life Science